This has been a whirlwind year in Washington, D.C., with the inauguration of President Donald Trump and the swearing in of a new Republican majority in the U.S. Senate. The “Republican trifecta” of the House, Senate, and administration has led to stalled progress with cannabis legalization, [...]
In her new bi-weekly series for Cannabis Health, Dr Sue Clenton, Consultant Oncologist and Medical Director at Releaf Cannabis Clinic, shares her insight from the front line of an emerging field of medicine, taking readers inside the clinic and offering a doctor’s perspective on what it [...]
A large UK study suggests that people who use cannabis to self-medicate for pain or anxiety may be more likely to experience paranoia, prompting calls for improved patient monitoring in private prescribing. Researchers from King’s College London recently published the first findings from the Cannabis & [...]
At the recent Business of Cannabis event in New York, Robert Sciarrone, Chief Revenue Officer at Curaleaf, shared an MSO’s insider view on why he believes New York is poised to become the best cannabis market on the planet. Sciarrone began by reflecting on his early [...]
From endometriosis and chronic pelvic pain to PMDD and menopause, more women are turning to cannabis-based medicine, but what do we know and where do we still need more research? In the face of long NHS waiting lists and a lack of options in mainstream healthcare, [...]
Families have marked the seventh anniversary of the legalisation of medical cannabis in the UK with further calls for urgent government action on NHS access. Dozens of families attended Westminster on Tuesday (4 November) to meet with cross-party MPs and demand immediate action to address the [...]
Cannabis products are increasingly held to the same standards as food and pharmaceuticals, and that means verifying how their potency and composition change over time. Cannabis stability testing provides the data needed to establish reliable shelf life, confirm product consistency, and guide formulation optimization for improved [...]
As cannabis production scales and testing standards tighten, cultivators face increasing pressure to ensure their products are free from harmful microbes without compromising quality. Decontamination, the process of removing or killing microorganisms, has become a common step in post-harvest processing. Traditional methods come with trade-offs that [...]
The endocannabinoid system (ECS) helps regulate vital bodily functions from mood and pain to immune response, yet it remains one of medicine’s best-kept secrets. We unpack the science behind the ECS and its significance in a range of chronic conditions. The endocannabinoid system (ECS) plays a [...]
Zurich’s flagship adult-use cannabis trial, Züri Can, could now run until 2028 after city officials applied this week to extend the project by two years, citing strong early results in reducing illicit sales and promoting safer consumption. The move comes as the Swiss Federal Government continues [...]
Healthcare professionals attending the Cannabis Health Symposium next month will be able to earn CPD points to support their professional development. The Cannabis Health Symposium is a Continuing Professional Development (CPD)-accredited event, meaning attendees can earn professional development credits as a result of their participation. The [...]
MariMed, one of the nation’s leading multi-state cannabis operators, began in the medical cannabis market and expanded into adult-use as states legalized. Through this growth, the company has remained true to its “medical-first” approach, ensuring that product quality, safety, and consistency remain at the core of [...]
For decades, cannabis has lived in a research dead zone. Federal prohibition has blocked meaningful grants, limited clinical trials, and left millions of people with cancer relying on anecdotal evidence for treatment rather than data. As founders of E.R.I.C. Cancer Playbook, we refused to accept that. [...]
Jason Ambrosino, a disabled Army veteran and founder of Veterans Holdings, entered the New York market in 2019 under the state’s hemp program with the goal of cultivating and manufacturing cannabis. But despite holding a 5,000-square-foot indoor cultivation license, he decided not to build out his [...]
In her new bi-weekly series for Cannabis Health, Dr Sue Clenton, Consultant Oncologist and Medical Director at Releaf Cannabis Clinic, shares her insight from the front line of an emerging field of medicine, taking readers inside the clinic and offering a doctor’s perspective on what it [...]
Almost seven years since medical cannabis was legalised in the UK on 1st November 2018, less than 1% of the UK’s approximate 100,000 doctors on the General Medical Council (GMC) Specialist Register have the training required to prescribe medical cannabis. While the UK’s medical cannabis market [...]
A growing number of patients are now prescribed medical cannabis for common mental health issues and neurodiverse conditions, such as autism and ADHD. Ahead of Cannabis Health Symposium next month, we examine the research and real-world evidence behind the use of cannabis-based medicines in psychiatry. Many [...]
A new health-tech company, EM2P2, has launched CannaLnx, a HIPAA-compliant platform it claims will make medical cannabis reimbursable under traditional health insurance plans for the first time in the U.S. The system, announced in partnership with the American Council of Cannabis Medicine (ACCM), is described as [...]
Curaleaf Laboratories has been confirmed as headline sponsor of the inaugural Cannabis Health Symposium, taking place on 25 November 2025 at Conway Hall, London. The event, delivered in partnership with the Medical Cannabis Clinicians Society (MCCS), will focus on strengthening clinical understanding and confidence in prescribing [...]
The Advisory Council on the Misuse of Drugs (ACMD) has closed its latest call for evidence into the impact of medical cannabis legalisation, in what will mark the most comprehensive review of the UK’s cannabis-based products for medicinal use (CBPM) framework since it was introduced in [...]
Most cannabis dispensaries are small businesses. That often means they operate on tight margins and require employees to take on roles outside their typical job descriptions. It’s common for owners or general managers to handle HR and payroll functions themselves. What begins as an understandable cost-saving measure, however, [...]
Multiple scientific studies and lab results have provided compelling evidence that terpenes and volatile metabolites in cannabis rapidly degrade when exposed to light, oxygen, heat, and time, and therefore, reduce the entourage effect that depends on a specific balance of cannabinoids and terpenes. Because of this, [...]
How one oncologist is helping redefine patient care and the future of integrated healthcare. Medical cannabis is starting to have a very different kind of conversation in the UK. From mainstream voices like Rory Cellan-Jones exploring patient experiences on his Movers & Shakers podcast, to growing [...]
German pharmaceutical company Vertanical believes it is on course to deliver the first ‘whole-plant’, cannabis medicine with international approval. After seven years of endeavour, and an investment of over $250m, its VER-01 chronic pain-relief drug has passed a Phase 3 trial in its home market. As [...]
As the prevalence of dementia and other neurodegenerative conditions continues to rise globally, there is growing interest in the role of cannabis-based medicines in symptom management. A small number of studies, combined with real-world clinical experience is beginning to provide important insights into the potential of [...]
Target’s decision to start selling hemp-derived THC beverages marks a major milestone for the cannabis industry and a reality check for brands hoping to follow. Selling into mass retail is not just about scaling production or packaging appeal. It requires proving that your product meets the [...]
Medical cannabis patients will host a major educational event in the UK next month, aiming to bridge the gap between patients and healthcare professionals through evidence, empathy and lived experience. The international patient-led organisation We, The Patients, will bring its educational series to London next month [...]
In cannabis, it sometimes feels like every financial conversation ends the same way: “If not for 280E, we’d be thriving.” That line gets repeated in boardrooms and investor decks across the country, and for good reason. Section 280E has choked margins, slowed growth, and kept great [...]
Global cannabis trade is well underway as legalized countries move forward to establish a supply chain infrastructure in a newly formed and rapidly evolving industry. At the forefront of transportation logistics is Cannabilog, an Israeli company led by pharmaceutical industry veteran Yoram Eshel. In an interview, [...]
Experts say real-world evidence could offer crucial insights into how these medicines work in practice, and help widen access for patients. For the last 50 years, randomised controlled trials (RCTs) have been considered the ‘gold standard’ research methodology for measuring the safety and efficacy of new [...]
In a historic move, Spain’s Council of Ministers has approved a long-awaited Royal Decree regulating the medicinal use of cannabis preparations in hospital settings. Following years of advocacy on behalf of patients and campaigners, the decision marks a decisive step toward the integration of medical cannabis [...]
As our bodies age, the mechanisms that keep our systems humming, such as immune regulation, metabolism, and neural repair, gradually erode. That loss of homeostasis is the culprit behind many age-related disorders, from cognitive decline to metabolic dysfunction. Scientists are beginning to explore whether cannabis or [...]
Germany’s booming cannabis market, which Prohibition Partners now estimates to be worth around €670m, is entering uncertain and potentially treacherous territory. As the landmark CanG Act approaches its second year, it has become a highly charged and increasingly divisive issue politically, culturally, and medically. With the [...]
Q&A with Brendan McGee, Founder, Silver Therapeutics Tell us about your product(s). What do you make or sell, and what should people know about it? At Silver Therapeutics, we’re driven to curate experiences that meet people where they are. From flower to prerolls to vapes, we [...]
Alibi Cannabis website. Q&A Tell us about your product(s). What do you make or sell, and what should people know about it? Our roots are in cultivation, so everything starts with high-quality flowers. In Oregon, our flower has won multiple awards, and we bring that focus [...]
Website: rosareta.com Tell us about your product(s). What do you make or sell, and what should people know about it? Rosa Reta crafts solventless cannabis Live Rosin vapes (All-In-One), Bubble Hash Infused prerolls, and Rosin infused gummies. We focus on clean processing, full-spectrum flavor, and consistent quality [...]
The cannabis industry’s fragmented foundation is creating a host of problems tied to the lack of federal legalization. Many experts believe that without a national medical cannabis framework, the future of cannabis as a medicine in America could leave patients unprotected, research underfunded, and the industry [...]
At PatientsCann UK, we represent the voices of patients who rely on safe, effective, and regulated access to medical cannabis. Since its legalisation in 2018, many people have continued to face unnecessary barriers to treatment, from stigma and misinformation to the limited availability of NHS prescriptions. For thousands of patients, private prescriptions remain the only viable route to accessing the medicine they need. That’s why the Department of Health and Social Care’s “Private (non-NHS) Prescribing: Call for Evidence” is such an important opportunity. This review could influence how private prescribing works in the UK, including how cannabis-based medicines are accessed, regulated, and supported by clinicians. Why This Matters The call for evidence invites responses from across the healthcare system, including clinicians, prescribers, pharmacists, healthcare organisations, and patient groups. While the questions are primarily aimed at professionals, it is crucial that patients and carers also share their experiences. By contributing evidence and lived experience, we can help policymakers understand: How private prescribing supports patients who are unable to access NHS treatment. The challenges of affordability, continuity of care, and stigma in private medical cannabis access. The need for greater clinical education and confidence around prescribing cannabis-based medicines. The importance of protecting safe, regulated, and equitable access for all patients. Our Position PatientsCann UK believes that this review must:Protect the right of patients to access regulated medical cannabis safely and affordably.Promote fairness and consistency between NHS and private prescribing pathways.Address stigma and empower clinicians to prescribe based on evidence, not fear.Encourage more research, education, and evidence-based practice across the medical field. This consultation provides a rare chance to shape how the UK approaches private prescribing, and to ensure medical cannabis patients are not overlooked. How to Take Part Your experience is evidence — share it.The Private (non-NHS) Prescribing: Call for Evidence is now open to submissions from individuals and organisations with knowledge or experience of private prescribing. Visit: Private (non-NHS) Prescribing: Call for Evidence – GOV.UKDeadline: 11:59 pm, 4 November 2025 You do not need to answer every question, but you must select Submit at the end for your response to count. How Patients Can Encourage Healthcare Professionals You can play an important role in raising awareness of this consultation within your own care networks. Here are a few ways to help: Start the conversation. Mention the review to your prescribing clinician, pharmacist, or nurse and let them know the deadline. Many professionals may not yet be aware of it. Share the link. Send your clinic, GP practice, or specialist the official GOV.UK consultation page and encourage them to share it with colleagues. Speak to both sides. Whether your care is through a private medical cannabis clinic or the NHS, professionals across both systems can contribute valuable insight on access, patient safety, and clinical challenges. Explain why it matters. Let them know that evidence from healthcare professionals — especially those working with medical cannabis — can directly shape how government policy supports safer and fairer access for patients. Spread awareness. Share our post and tag your clinic, pharmacy, or medical organisation on social media to encourage wider participation. Your voice can help ensure that both patients and healthcare professionals are represented in this important review. Important Note This consultation is separate from the ACMD call for evidence on cannabis-based medicinal products, which focuses on clinical data and scheduling. Both reviews are crucial, and we encourage responses to each. Together, we can ensure that clinicians, patients, and organisations play a leading role in shaping an equitable and evidence-based future for medical cannabis access in the UK. 💚
The post Help Shape The Future of Medical Cannabis first appeared on PatientsCann UK.
The cannabis industry is a fertile ground for aspiring entrepreneurs, holding the promise of a modern-day gold rush. Yet beneath the surface of opportunity lies a minefield of obstacles. Success requires navigating a steep learning curve, managing high operational costs, and mastering a complex supply chain [...]
Dr Sue Clenton, Medical Director of Releaf cannabis clinic explains what it takes to go from a few hundred to thousands of patients, without compromising on the quality of care. When people talk about growth in healthcare, the conversation often centres on numbers – the number [...]
New guidelines around THC levels, dosages, and eligibility, aim to bring more clarity and consistency to the practice of prescribing cannabis-based medicines in the UK. Almost seven years since medical cannabis was legalised in the UK, around 180 specialist consultants are now actively prescribing. But almost [...]
The Advisory Council on the Misuse of Drugs (ACMD) is reviewing cannabis-based products for medicinal use (CBPMs).
The post PatientsCann UK Statement on the ACMD Review of Medical Cannabis first appeared on PatientsCann UK.
Words by Lawrence Purkiss and Sarah Sinclair Portugal hosted its seventh international conference on medical cannabis (PTMC) in central Lisbon last week, amid a growing feeling that the country – a once-thriving hub for European cannabis exports – is at an inflection point. Discussion among speakers [...]
Beyond its wellness benefits, cannabis carries a rich and diverse cultural legacy that spans the globe. In a technical paper submitted to Mondiacult 2025, the Cannabis Embassy calls for global recognition of cannabis cultures as an integral part of humanity’s cultural diversity, and as essential to [...]
On April 1, 2024, Germany launched Pillar 1 of its adult-use legalization framework, building on its established medical cannabis program that has been in place since 2017. Since then, the number of medical patients has surged, as prescriptions remain the only fully legal access point for [...]
The next evolution of marketing in the cannabis industry has arrived. Global Compliance Application Corp. (GCAC), a publicly traded Canadian company specializing in blockchain technology, has launched Citizen Green, a connected TV (CTV) channel designed to educate viewers on various aspects of the cannabis industry. The [...]
By Rupa Shah, Head of Compliance at Releaf The conversation around workers’ rights and medical cannabis is still at a very early stage in the UK. Despite the fact that thousands of patients now access cannabis-based medicines legally through prescription, the framework remains poorly understood by [...]
Over the course of three years, across 13 regulated U.S. markets, BayMedica, a company specializing in the production and distribution of rare cannabinoids, identified three key insights into market demand for these compounds. First, products featuring THCV posted a 23.7% higher average retail margin than comparable [...]
Mental health advocate and one half of music duo Rizzle Kicks, Jordan Stephens, is collaborating with medical cannabis clinic, Alternaleaf, to shed light on the role of alternative treatments in supporting mental wellbeing. Stephens, who is currently touring with Rizzle Kicks as part of their comeback [...]
The UK’s medical cannabis industry is now the second largest in Europe, second only to Germany, thanks to consistent and sustained growth over the last seven years. While this has seen thousands of new patients gain access to medical cannabis, it still represents just a fraction [...]
Copyright © 2020 – 2025 | The Cannabis Pages | All Rights Reserved | Important Notice | The Cannabis Pages “TCP” is an information resource for medical cannabis patients and prescribers. Nothing on the site should be construed as a promotion or inducement. TCP does not promote any product or represent that the products mentioned on TCP’s website are treatment for any kind of medical condition. TCP cannot guarantee that information provided is error-free or complete and is not responsible for the quality of the information provided by users. Cannabis is an unlicensed medication which can only be administered under the supervision of a licensed physician.
